GERN - Geron Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.6400
+0.0500 (+3.14%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Williams %R

Williams %R

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close1.5900
Open1.6300
Bid0.0000 x 2900
Ask0.0000 x 36100
Day's Range1.6000 - 1.7100
52 Week Range0.7500 - 2.4000
Volume2,347,883
Avg. Volume2,492,540
Market Cap328.594M
Beta (5Y Monthly)1.65
PE Ratio (TTM)N/A
EPS (TTM)-0.3600
Earnings DateMay 28, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.38
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Geron Corporation Announces the Closing of its Public Offering of Common Stock and Warrants

    Geron Corporation (GERN), a late-stage clinical biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 107,049,375 shares of its common stock and pre-funded warrants to purchase 8,335,239 shares of common stock, together with accompanying warrants to purchase 57,692,307 shares of common stock. The common stock and pre-funded warrants were sold in combination with an accompanying warrant to purchase 0.5 of a share of common stock issued for each share of common stock or pre-funded warrant sold. The combined offering price to the public of each share of common stock and accompanying warrant was $1.30.

  • Benzinga

    P/E Ratio Insights for Geron

    In the current market session, Geron Inc. (NASDAQ:GERN) is trading at $1.52, after a 22.19% decrease. However, over the past month, the stock increased by 31.47%, and in the past year, by 0.33%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session.Assuming that all other factors are held constant, this could present itself as an opportunity for shareholders trying to capitalize on the higher share price. The stock is currently under from its 52 week high by 36.46%.The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E indicates that shareholders do not expect the stock to perform better in the future, and that the company is probably undervalued. It shows that shareholders are less than willing to pay a high share price, because they do not expect the company to exhibit growth, in terms of future earnings.Depending on the particular phase of a business cycle, some industries will perform better than others.Compared to the aggregate P/E ratio of the 0.73 in the biotechnology industry, Geron has a lower P/E ratio of 0.0. Shareholders might be inclined to think that they might perform worse than its industry peers. It's also possible that the stock is undervalued.Price to earnings ratio is not always a great indicator of the company's performance. Depending on the earnings makeup of a company, investors may not be able to attain key insights from trailing earnings.See more from Benzinga * 20 Healthcare Stocks Moving In Friday's Pre-Market Session * Stocks That Hit 52-Week Highs On Monday(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • MarketWatch

    Geron's stock tumbles after large share offering prices at 34% discount

    Shares of Geron Corp. plunged 26% in premarket trading Friday, after the biopharmaceutical company's large public offering of stock priced at a 34% discount. The stock offering comes about a week after the stock surged to a near 2-year high after the company announced "very encouraging durability data" regarding its cancer treatment imetelstat. On Friday, the company said its offering of 107.05 million common shares priced at $1.30, after the stock closed Thursday at $1.96. The offering represented about 53% of the shares outstanding. The company also offered pre-funded warrants to buy 8.34 million shares, together with warrants to buy 57.69 million shares. The company said it plans to use the proceeds from the offerings to fund its ongoing IMerge Phase 3 trial in lower risk myelodysplastic syndromes to top-line results, its planned Phase 3 clinical trial in refractory myelofibrosis to complete patient enrollment, and for working capital and general corporate purposes. The stock has run up 44.1% year to date through Thursday, while the iShares Nasdaq Biotechnology ETF has gained 9.9% and the S&P 500 has lost 8.7%.

  • GlobeNewswire

    Geron Corporation Announces the Pricing of its Public Offering of Common Stock and Warrants

    Geron Corporation (GERN), a late-stage clinical biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 107,049,375 shares of its common stock and pre-funded warrants to purchase 8,335,239 shares of common stock, together with accompanying warrants to purchase 57,692,307 shares of common stock. The common stock and pre-funded warrants will be sold in combination with an accompanying warrant to purchase 0.5 of a share of common stock issued for each share of common stock or pre-funded warrant sold.

  • GlobeNewswire

    Geron Corporation Announces Proposed Public Offering of Common Stock and Warrants

    Geron Corporation (GERN), a late-stage clinical biopharmaceutical company, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of its common stock in an underwritten public offering. All of the securities in the proposed offering are to be sold by Geron. A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock and accompanying warrants described above was previously filed with the Securities and Exchange Commission (SEC) and subsequently declared effective by the SEC.

  • GlobeNewswire

    Geron Announces Plans for Imetelstat Phase 3 Clinical Trial in Myelofibrosis and Other Updates

    Geron Corporation (GERN), a late-stage clinical biopharmaceutical company, today announced plans for a Phase 3 clinical trial in MF patients who are refractory to treatment with a janus kinase (JAK) inhibitor, including trial design and expected timelines for trial start and future data readouts. Geron also provided an update on its ongoing IMerge Phase 3 clinical trial in lower risk MDS and reported revised fiscal year 2020 operating expense guidance.

  • Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    Business Wire

    Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    Geron Corporation (Nasdaq: GERN) today reported that it has granted a non-statutory stock option to purchase an aggregate of 70,000 shares of Geron common stock as an inducement to a newly-hired employee in connection with commencement of employment with the Company.

  • Why Geron Stock Soared 23.4% Today
    Motley Fool

    Why Geron Stock Soared 23.4% Today

    The bio pharmaceutical announced fresh data on imetelstat that it will present at a key conference next month.

  • 3 “Strong Buy” Penny Stocks With Triple-Digit Upside
    TipRanks

    3 “Strong Buy” Penny Stocks With Triple-Digit Upside

    Given the troubling state of the U.S. economy, what’s driving the bullish sentiment on Wall Street? Stimulus.Among the bulls is chief investment strategist at CFRA, Sam Stovall, who estimates that the S&P 500 will hit 3,435 within a year. From current levels, this would reflect a double-digit gain, and come in above the 3,393 high-point posted on February 19. Back in March, he even went so far as to call for a new high in the third quarter, but since then he has updated his forecasts.“We’ve had a lot of people compare it with the Crash of ’29, the Depression of the 1930s, etc. But back then, you had the government actually tightening their reins, balancing their budget — you did not have a reactive Federal Reserve,” Stovall stated. He added, “Who’s to say we don’t go for a retest first? That’s a normal situation. However, I don’t think we’re going to get an even lower low because of the stimulus already injected into the system.”To this end, risk-tolerant investors are looking to take advantage of lower share prices, which present more attractive entry points. What’s the advantage of stocks with bargain price tags, specifically those trading for less than $5 per share? Should these names, which are deemed “penny stocks," experience even minor share price appreciation, it can translate to massive percentage gains.Therefore, huge returns are on the table, but penny stocks aren’t everyone’s cup of tea. Some argue that there could be a good reason they are trading at such low levels, and that the risk outweighs the potential rewards. Understanding the risk involved, we wanted to see if we could track down any compelling penny stocks in the healthcare space. Using TipRanks’ database, we pinpointed three that have received enough support from Wall Street analysts to earn a “Strong Buy” consensus rating. The cherry on top? All three of the tickers could double in the next year. Let’s dive in.Marinus Pharmaceuticals, Inc. (MRNS)Focused on the development of neuropsychiatric therapeutics, Marinus is one of the top players in the orphan epileptic disorder space. Following a first quarter update on the company’s progress, Wall Street believes its long-term growth narrative is strong and that its $2.06 share price reflects the ideal entry point.As part of the update, management announced that the design and dosing for the RSE pivotal Phase 3 trial for its lead development candidate, ganaxolone (GNX), had been confirmed, with it set to begin in the third quarter. The co-primary endpoints for the trial are status cessation within 30 minutes and suppression for at least 24 hours, and it will be powered 90% to hopefully show 30% efficacy for GNX when compared to the placebo. Commenting for Oppenheimer, analyst Jay Olson said, “We view pivotal Phase 3 design as similar to positive Phase 2 trial while benefiting from longer dosing with 12 hours exposure vs. 8 hours prior. MRNS expects top-line data in the first half of 2022.”Additionally, the company finished enrolling participants for its CDD pivotal Phase 3 MARIGOLD trial, with the top-line data also slated for release in the third quarter. Olson argues that the discontinuation rate of less than 10% and high enrollment rate imply that tolerability levels are “favorable." The analyst added, “Pre-commercialization and NDA filing preparations remain on track despite COVID-19. We believe MRNS could have a substantial competitive advantage as a first mover.”If that wasn’t enough, Olson thinks the TSC Phase 2 open-label trial, which should start screening patients in Q2 and could see top-line data published in Q1 2021, could serve as a significant catalyst for shares. While COVID-19's impact on enrollment caused management to downsize the PRE Phase 3 VIOLET trial into a Phase 2 proof-of-concept trial in order to reprioritize resources, MRNS still has plenty going for it.“We view MRNS as well-positioned despite potential COVID-19 disruptions, with $77.8 million cash balance providing runway into 3Q21. We view MRNS's pipeline as attractive with multiple opportunities and several key near-term catalysts. We believe the current share price provides an attractive entry point,” Olson explained.To this end, Olson kept his Outperform call and $6 price target as is. Should this target be met, a twelve-month gain of 191% could be in store. (To watch Olson’s track record, click here) What does the rest of the Street think about Marinus’ long-term growth prospects? It turns out that other analysts also have high hopes. Only Buy ratings have been received in the last three months, so the consensus rating is a Strong Buy. In addition, the $5.50 average price target suggests 168% upside potential. (See Marinus stock analysis on TipRanks)Arbutus Biopharma Corporation (ABUS)With a diverse chronic hepatitis B virus (HBV) product pipeline including direct antiviral, host targeting and immune-based approaches, Arbutus Biopharma wants to develop a cure for the condition. Currently going for $1.65 apiece, several members of the Street think now is the time to get on board as multiple catalysts are fast-approaching.On May 11, the company revealed that it plans to share further results from the week 12 portion of the 60 mg single-dose cohort evaluating its lead candidate, a GalNAc delivered RNAi compound, AB-729, in the second quarter of 2020.Five-star analyst Mayank Mamtani, of B.Riley FBR, points out that preliminary data from the Phase 1a/1b AB-729 HBV study showed an HBsAg reduction comparable to advanced RNAi peers, even though it enrolled difficult to treat e-antigen negative patients. As HBsAg reduction rose during the study, the analyst argues that this increases the chances of successful follow-up data.On top of this, ABUS has several ongoing preclinical studies that are progressing right on track, enabling it to advance its next-generation oral capsid inhibitor, AB-836, into the clinic in 2021. This goes hand in hand with the company’s research efforts to develop an oral HBV RNA-destabilizer and an oral anti-PD-L1 inhibitor. Expounding on this, Mamtani commented, “Building on learnings from the previously discontinued AB-506, AB-836 offers increased potency and an enhanced resistance profile with ongoing IND-enabling studies inclusive of a new assay to help better characterize the safety profile.” It should also be noted that ABUS is going to start working on a therapy for coronaviruses, specifically targeting RNA-dependent polymerase, nsp12, and viral protease, which play key roles in the replication and transcription cycle of COVID-19. Mamtani thinks this approach is promising as Gilead’s experimental COVID-19 treatment, remdesivir, is a nucleotide analog that binds nsp12, which inhibits viral proliferation and produces clinical benefits.Mamtani added, “Nsp12 has also been implicated in HCV, HIV, and, notably, HBV, areas in which ABUS has extensive antiviral development expertise. In concert with the biotech and pharma COVID-19 consortium, ABUS anticipates pooling resources along with leveraging primary screening and lead optimization capabilities to advance novel candidates against known and unknown targets, which works ideally as a pan coronavirus agent in order to also prepare for future outbreaks.”Based on all of the above, it’s no wonder Mamtani reiterated his bullish call. Given the $6 price target, shares could soar 253% in the next twelve months. (To watch Mamtani’s track record, click here) Turning now to the rest of the Street, other analysts are on the same page. With 100% Street support, or 3 Buy ratings to be exact, the consensus is unanimous: ABUS is a Strong Buy. The $5 average price target brings the upside potential to 198.5%. (See Arbutus Biopharma stock analysis on TipRanks)Geron Corporation (GERN)Last but not least we have Geron, which is primarily focused on the development of imetelstat, a small molecule telomerase inhibitor active in the treatment of highly transfusion-dependent MDS and r/r myelofibrosis (MF). While it’s very likely that the company will experience some delays as a result of COVID-19, the Street cites its promising technology and bargain $1.36 share price as making it a compelling healthcare play.Some investors have expressed concern regarding GERN’s announcement that it won’t be able to complete enrollment for the Phase 3 IMerge trial by 2020 due to the impact of COVID-19. BTIG analyst Thomas Shrader acknowledges that the delay will push back imetelstat’s approval and launch, which he now thinks will come in 2024 instead of 2023. However, he argued, “Geron’s patients are as desperate as they come in r/r MDS and AML and we expect data to date leave physicians and patients highly motivated to find something to try.”Further explaining the MDS opportunity, Shrader believes the program demonstrates robust levels of durability. Not only does the five-star analyst call the 24-week RBC-TI rate “highly compelling”, but he also highlights the strong safety profile.Shrader said, “Greater than 90% of patients with neutropenias and thrombocytopenias had these AEs resolve prior to the next dose. This reversibility is in contrast to both HMAs and Revlimid where these toxicities result in drug interruptions. A KOL recently commented that the high 68% HI-E response suggests most patients receive some benefit – making any subsequent trials very easy to enroll.”It should be noted that previously, its IMbark trial had a 32% discontinuation rate thanks to lack of efficacy, but Shrader thinks “these discontinuations may have been premature due to the drug’s slow onset of action and its ‘black box nature’ during the trial.” He added, “Based on increased understanding of how imetelstat works and its promise as a therapeutic, this discontinuation rate is likely to be low in subsequent trials. Imetelstat seems likely to be used after luspatercept in RS+ MDS but could be the only drug after ESAs in other forms of the disease (including RS-).”With GERN working out the MF trial design and hoping to discuss the regulatory path forward with the FDA in Q2, the deal is sealed for Shrader. Along with a Buy rating, he did trim the price target from $4 to $3, but this still leaves room for 114% upside potential. (To watch Shrader’s track record, click here)All in all, other analysts echo Shrader’s sentiment. 3 Buys and no Holds or Sells add up to a Strong Buy consensus rating. Based on the $3.50 average price target, the upside potential comes in at 149%. (See Geron stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

  • Geron Announces Four Imetelstat Presentations at the Virtual Edition of the European Hematology Association Annual Congress
    Business Wire

    Geron Announces Four Imetelstat Presentations at the Virtual Edition of the European Hematology Association Annual Congress

    Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that four abstracts containing new clinical data and analyses related to imetelstat, the Company’s first-in-class telomerase inhibitor, have been accepted for presentation at the Virtual Edition of the European Hematology Association (EHA) Annual Congress to be held online from June 11-14, 2020. The abstracts are available on the EHA website at www.ehaweb.org/congress.

  • Earnings Preview: Geron (GERN) Q1 Earnings Expected to Decline
    Zacks

    Earnings Preview: Geron (GERN) Q1 Earnings Expected to Decline

    Geron (GERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    Business Wire

    Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 500,000 shares of Geron common stock as inducements to two newly-hired employees in connection with commencement of employment with the Company.

  • Clinical trials in the age of COVID: Shelter-in-place, hospital restrictions cause drug study delays
    American City Business Journals

    Clinical trials in the age of COVID: Shelter-in-place, hospital restrictions cause drug study delays

    In the span of eight days last month, CytomX Therapeutics Inc. landed a collaboration with Astellas Pharma and captured a $40 million milestone payment from AbbVie Inc. as it preps for a mid-stage cancer clinical trial. “It’s a challenging time for our industry,” said CytomX President and CEO Sean McCarthy.

  • GlobeNewswire

    Geron to Present at Needham Virtual Healthcare Conference

    MENLO PARK, Calif., April 08, 2020 -- Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, is scheduled to.

  • Here's Why We're Not Too Worried About Geron's (NASDAQ:GERN) Cash Burn Situation
    Simply Wall St.

    Here's Why We're Not Too Worried About Geron's (NASDAQ:GERN) Cash Burn Situation

    We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

  • Thomson Reuters StreetEvents

    Edited Transcript of GERN earnings conference call or presentation 12-Mar-20 8:30pm GMT

    Q4 2019 Geron Corp Earnings Call

  • GlobeNewswire

    Geron Provides COVID-19 Related Business Update

    Geron Corporation (GERN), a late-stage clinical development biopharmaceutical company, today announced an update to information from its March 12 year-end conference call related to the impact of the COVID-19 pandemic on the Company’s business, and described the measures being taken to protect the safety of Geron’s employees and patients in its clinical trials. Due to these circumstances, we no longer expect to complete enrollment in the IMerge Phase 3 trial or to commence our proof of concept study in high risk MDS and AML by the end of 2020, as we had originally planned. Given the fluid and rapidly evolving consequences of COVID-19, we cannot predict the long-term effect on IMerge timelines until we have more visibility on the length of the crisis and its impact on our IMerge clinical trial activities.

  • ACCESSWIRE

    CLASS ACTION UPDATE for GERN, HPQ and CAN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

    NEW YORK, NY / ACCESSWIRE / March 23, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders ...

  • DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Geron Corporation and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
    ACCESSWIRE

    DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Geron Corporation and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / March 23, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Geron Corporation ("Geron" or "the Company") (NASDAQ:GERN) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who suffered a loss between March 19, 2018 and September 26, 2018, inclusive (the "Class Period") are encouraged to contact the firm by the March 23, 2020 lead plaintiff deadline.

  • ACCESSWIRE

    The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of QD, GERN and AAN

    NEW YORK, NY / ACCESSWIRE / March 23, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate ...

  • MONDAY DEADLINE ALERT: The Schall Law Firm Announces it is Investigating Claims Against Geron Corporation and Encourages Investors with Losses to Contact the Firm
    Business Wire

    MONDAY DEADLINE ALERT: The Schall Law Firm Announces it is Investigating Claims Against Geron Corporation and Encourages Investors with Losses to Contact the Firm

    MONDAY DEADLINE ALERT: The Schall Law Firm Announces it is Investigating Claims Against Geron Corporation.

  • ACCESSWIRE

    GERN FINAL DEADLINE - Bronstein, Gewirtz & Grossman, LLC Reminds Geron Corporation Investors of Class Action and Encourages Investors to Contact the Firm

    This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934. The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) misled investors about the results of a clinical drug study of imetelstat called IMbark; and (2) as a result, defendants' statements about Geron's business, operations, and prospects were materially false and misleading and lacked a reasonable basis at all relevant times.

  • ACCESSWIRE

    HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Geron Corporation (GERN) Investors: Application Deadline Today, Investors with Losses Should Contact Firm Immediately

    SAN FRANCISCO, CA / ACCESSWIRE / March 23, 2020 / Hagens Berman urges investors in Geron Corporation (NASDAQ: GERN) who have suffered significant losses to submit their losses now to learn if they qualify ...

  • FINAL DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Geron Corporation and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
    ACCESSWIRE

    FINAL DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Geron Corporation and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / March 23, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Geron Corporation ("Geron" or "the Company") (NASDAQ:GERN) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who suffered a loss between March 19, 2018 and September 26, 2018, inclusive (the "Class Period") are encouraged to contact the firm by the March 23, 2020 lead plaintiff deadline.

  • ACCESSWIRE

    HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Geron Corporation (GERN) Investors: Application Deadline Tomorrow, Investors with Losses Encouraged to Contact Firm

    SAN FRANCISCO, CA / ACCESSWIRE / March 22, 2020 / Hagens Berman urges investors in Geron Corporation (NASDAQ: GERN) who have suffered significant losses to submit their losses now to learn if they qualify ...